Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR2 | O95136 | 8/20 | 0.67 |
| ▸ | S1PR1 | P21453 | 8/20 | 0.67 |
| ▸ | S1PR3 | Q99500 | 8/20 | 0.67 |
| ▸ | S1PR4 | O95977 | 5/20 | 0.67 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.55 |
| ▸ | LAP3 | P28838 | 1/20 | 0.55 |
| ▸ | SGPL1 | O95470 | 4/20 | 0.54 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.53 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.53 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.53 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.53 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21428471 | 1.00 | S1PR2 (0.67) | S1PR2S1PR1S1PR3S1PR4S1PR5 | |
| SCHEMBL22910697 | 1.00 | S1PR2 (0.67) | S1PR2S1PR1S1PR3S1PR4S1PR5 | |
| SCHEMBL13326629 | 0.85 | S1PR1 (0.56) | S1PR2S1PR1S1PR3S1PR4S1PR5 | |
| SCHEMBL16575596 | 0.85 | PLA2G2A (0.59) | S1PR2S1PR1S1PR3S1PR4LAP3 | |
| SCHEMBL21346930 | 0.81 | LPAR3 (0.57) | SGPL1LPAR3LPAR1LPAR2SMPD1 | |
| SCHEMBL22844447 | 0.81 | LPAR3 (0.57) | SGPL1LPAR3LPAR1LPAR2SMPD1 | |
| SCHEMBL10781198 | 0.81 | LPAR3 (0.57) | SGPL1LPAR3LPAR1LPAR2SMPD1 | |
| SCHEMBL9632719 | 0.81 | LPAR3 (0.57) | SGPL1LPAR3LPAR1LPAR2SMPD1 | |
| SCHEMBL15966827 | 0.81 | LPAR3 (0.57) | SGPL1LPAR3LPAR1LPAR2SMPD1 | |
| SCHEMBL21141423 | 0.81 | LPAR3 (0.57) | SGPL1LPAR3LPAR1LPAR2SMPD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2117 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9328347-B2 | siRNA useful in the treatment of flavivirus infection | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2016-05-03 | — | — | US | claimed |
| US-8846631-B2 | MicroRNA compositions and methods | Regulus Therapeutics Inc. (US) | 2014-09-30 | — | — | US | claimed |
| US-20140287023-A1 | 5'-TRIPHOSPHATE OLIGORIBONUCLEOTIDES | UNIV MCGILL (CA) | 2014-09-25 | — | — | US | claimed |
| US-20140248336-A1 | SIRNA USEFUL IN THE TREATMENT OF FLAVIVIRUS INFECTION | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2014-09-04 | — | — | US | claimed |
| WO-2014124433-A1 | 5'-TRIPHOSPHATE OLIGORIBONUCLEOTIDES | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2014-08-14 | — | — | WO | claimed |
| WO-2013012835-A2 | SIRNA USEFUL IN THE TREATMENT OF FLAVIVIRUS INFECTION | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2013-01-24 | — | — | WO | claimed |
| JP-2003525017-A | — | — | 2003-08-26 | — | — | JP | claimed |
| JP-2002526072-A | — | — | 2002-08-20 | — | — | JP | claimed |
| JP-2002520051-A | — | — | 2002-07-09 | — | — | JP | claimed |
| EP-1115859-A2 | HAIRPIN HYBRIDIZER MOLECULES FOR MODULATION OF GENE EXPRESSION | RIBOZYME PHARMACEUTICALS, INC. (US) | 2001-07-18 | — | — | EP | claimed |
| EP-1098969-A2 | USE OF NUCLEIC ACID MOLECULES AS ANTIVIRAL AGENTS | RIBOZYME PHARMACEUTICALS, INC. (US) | 2001-05-16 | — | — | EP | claimed |
| EP-1071753-A2 | NUCLEIC ACID MOLECULES WITH NOVEL CHEMICAL COMPOSITIONS CAPABLE OF MODULATING GENE EXPRESSION | RIBOZYME PHARMACEUTICALS, INC. (US) | 2001-01-31 | — | — | EP | claimed |
| WO-2000017346-A2 | HAIRPIN HYBRIDIZER MOLECULES FOR MODULATION OF GENE EXPRESSION | RIBOZYME PHARMACEUTICALS, INC. (US) | 2000-03-30 | — | — | WO | claimed |
| WO-2000004141-A2 | USE OF NUCLEIC ACID MOLECULES AS ANTIVIRAL AGENTS | RIBOZYME PHARMACEUTICALS, INC. (US) | 2000-01-27 | — | — | WO | claimed |
| WO-1999054459-A2 | NUCLEIC ACID MOLECULES WITH NOVEL CHEMICAL COMPOSITIONS CAPABLE OF MODULATING GENE EXPRESSION | RIBOZYME PHARMACEUTICALS, INC. (US) | 1999-10-28 | — | — | WO | claimed |
| CN-119278206-A | Compositions and methods for treating liver disease with GPAM-targeted siRNA | 得克萨斯大学体系董事会 | 2025-01-07 | — | — | CN | disclosed |
| CN-119278205-A | Compositions and methods for treating liver disease with CIDEB-targeted siRNA | 得克萨斯大学体系董事会 | 2025-01-07 | — | — | CN | disclosed |
| WO-2000004141-A2 | USE OF NUCLEIC ACID MOLECULES AS ANTIVIRAL AGENTS | RIBOZYME PHARMACEUTICALS, INC. (US) | 2000-01-27 | — | — | WO | disclosed |
| WO-1999055857-A2 | NUCLEOSIDE TRIPHOSPHATES AND THEIR INCORPORATION INTO RIBOZYMES | RIBOZYME PHARMACEUTICALS, INC. (US) | 1999-11-04 | — | — | WO | disclosed |
| WO-1999054459-A2 | NUCLEIC ACID MOLECULES WITH NOVEL CHEMICAL COMPOSITIONS CAPABLE OF MODULATING GENE EXPRESSION | RIBOZYME PHARMACEUTICALS, INC. (US) | 1999-10-28 | — | — | WO | disclosed |